FTFinancial Times·2hBusiness
score-0.40
AstraZeneca's $400bn Merger Talks with Bristol Myers Squibb End, Ending Potential Pharma Megadeal
Original
How AstraZeneca’s $400bn tie-up with US rival Bristol Myers unravelled
“The word 'unravelled' frames the failed merger as a collapse, emphasizing disappointment in a high-stakes business deal without implying human suffering.”